Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines
NCT ID: NCT02882893
Last Updated: 2016-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
238 participants
INTERVENTIONAL
2016-08-31
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
NCT03184363
Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line
NCT01629875
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
NCT06212960
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
NCT02568150
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
NCT07013279
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DWP450
Single-dose
Clostridium Botulinum A Toxin
Botox
Single-dose
Clostridium Botulinum A Toxin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clostridium Botulinum A Toxin
Clostridium Botulinum A Toxin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Konkuk University Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Daewoong Clinical
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Daewoong Clinical
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWP450005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.